Midazolam, used for COVID-19 care, is running low | DEA urged to raise narcotics production limit | Pfizer gets warning letter for sterile injectables plant in India
April 3, 2020
FDLI SmartBrief
News for the food and drug law communitySIGN UP ⋅   SHARE
Drugs & Biologics
An updated list of medications in shortage was released by the FDA on Thursday, and the list now includes the sedation drug midazolam, which is used for patients who require mechanical ventilation. Five manufacturers noted that the shortage was due to a higher demand for the drug.
Full Story: Regulatory Focus (4/2) 
Email
Physician and pharmacy advocates sent a letter to the the Drug Enforcement Administration urging the agency to increase production limits of injectable fentanyl, hydromorphone, morphine and other narcotics used for COVID-19 patients on ventilators to ensure hospitals have enough supplies during the pandemic. A senior DEA official said the agency is closely monitoring the situation and has been discussing measures it could implement to accelerate a quota increase if necessary, though the agency believes the current limit is high enough for companies to meet the surge in demand.
Full Story: Reuters (4/2) 
Email
Pfizer has received a warning letter from the FDA for its sterile injectables plant in Visakhapatnam, India. The facility's quality system does not ensure the "safety, effectiveness and quality of the sterile drugs" being shipped to the US, the letter states.
Full Story: FiercePharma (4/2) 
Email
Medical Devices
President Donald Trump issued a memorandum allowing HHS to use authority under the Defense Production Act to help Generic Electric, Medtronic and four other manufacturers to obtain supplies needed for ventilator production.
Full Story: The Hill (4/3) 
Email
The FDA is advising that it has not issued an emergency use authorization to a company called Bodysphere for a COVID-19 test despite false statements from the company that were distributed in the media. The agency is also warning people to be cautious of false coronavirus tests, drugs and devices.
Full Story: The New York Times (tiered subscription model) (4/1) 
Email
An FDA official said the agency will now permit imports of KN95 masks, described as the Chinese version of an N95 mask, due to the scarce supply of personal protective equipment in the US. The FDA said it's "ready and available to engage with importers to minimize disruptions during the importing process," but it noted importers may want to verify the authenticity of the masks.
Full Story: The Hill (4/2) 
Email
The FDA has given emergency use authorization to Cellex's SARS-CoV-2 serology test, which can deliver results within 15 minutes.
Full Story: Regulatory Focus (4/2) 
Email
European regulators have given CE mark approval to Genetic Signatures' SARS-CoV-2 test kit.
Full Story: 360Dx (tiered subscription model) (4/1) 
Email
Food and Drug Law Institute (FDLI) Highlights
Now Accepting Call for Proposals Through May 15
What high-level issues would you like to see addressed at FDLI's conferences? Proposals are now open for FDLI's Food Advertising, Labeling and Litigation Conference and Tobacco and Nicotine Products Regulation and Policy Conference. Submit a Proposal
Email
Calling All Law Students: FDLI's H. Thomas Austern Writing Competition | Deadline: June 19
Designed to encourage scholarship in the food and drug law field, FDLI's Austern Writing Competition seeks out students with papers analyzing areas of law affecting FDA-regulated industries. Students currently enrolled in a JD Program at ABA-accredited law schools or a 2019-2020 academic year graduate are eligible to participate. Submit Now
Email
LEARN MORE ABOUT FDLI:
About | Programs | Resources | Engage | Career
JOBS
  Associate - FDMD Regulatory
SIDLEY AUSTIN LLP - Washington, DC, US
  Food and Drug Associate
KELLER AND HECKMAN LLP - Washington, DC, US
View More Listings | Post a Job
The only thing ever achieved in life without effort is failure.
Francis of Assisi,
patron saint of Italy, animals, ecology
Email
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004